Nevertheless, biomarkers obtained via clinical and translational studies (the role of METTL13/FEAT in infection-driven neoplasia is a good example), as well as ongoing drug trials provide an avenue to examine fluctuations which reflect different stages of the immunopathological process. Here, METTL13 is linked to infection.